Susquehanna International Group
RXRX icon

Susquehanna International Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Susquehanna International Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.69M Sell
1,528,400
-930,000
-38% -$3.59M ﹤0.01% 4348
2025
Q4 		$10.1M Buy
2,458,400
+296,300
+14% +$1.47M ﹤0.01% 3032
2025
Q3 		$10.6M Buy
2,162,100
+499,000
+30% +$2.62M ﹤0.01% 2972
2025
Q2 		$8.42M Buy
1,663,100
+499,300
+43% +$2.45M ﹤0.01% 3093
2025
Q1 		$6.16M Buy
1,163,800
+19,000
+2% +$139K ﹤0.01% 3258
2024
Q4 		$7.74M Buy
1,144,800
+136,200
+14% +$916K ﹤0.01% 2972
2024
Q3 		$6.65M Sell
1,008,600
-246,200
-20% -$1.76M ﹤0.01% 3148
2024
Q2 		$9.41M Buy
1,254,800
+459,400
+58% +$4.01M ﹤0.01% 2564
2024
Q1 		$7.93M Buy
795,400
+594,400
+296% +$6.62M ﹤0.01% 2955
2023
Q4 		$1.98M Sell
201,000
-69,400
-26% -$495K ﹤0.01% 5367
2023
Q3 		$2.07M Buy
270,400
+186,100
+221% +$1.86M ﹤0.01% 5053
2023
Q2 		$630K Buy
84,300
+52,100
+162% +$365K ﹤0.01% 7768
2023
Q1 		$215K Buy
32,200
+20,500
+175% +$163K ﹤0.01% 10448
2022
Q4 		$90.2K Sell
11,700
-3,300
-22% -$32.4K ﹤0.01% 11048
2022
Q3 		$160K Sell
15,000
-11,800
-44% -$120K ﹤0.01% 11149
2022
Q2 		$218K Sell
26,800
-2,900
-10% -$19.4K ﹤0.01% 10429
2022
Q1 		$213K Sell
29,700
-19,300
-39% -$205K ﹤0.01% 11091
2021
Q4 		$839K Buy
49,000
+30,700
+168% +$578K ﹤0.01% 7762
2021
Q3 		$421K Buy
+18,300
New +$519K ﹤0.01% 9818

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's RXRX Position: Q1 2026 in Review

Susquehanna International Group reduced its Recursion Pharmaceuticals (RXRX) stake by 3.9% in Q1 2026, selling an estimated $660K and leaving 4,225,277 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

Susquehanna International Group first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $26.3M in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Susquehanna International Group held 4,225,277 shares of Recursion Pharmaceuticals worth $13M as of Q1 2026.
  • Susquehanna International Group sold 170,827 Recursion Pharmaceuticals shares in Q1 2026, an estimated $660K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2740 holding.
  • Susquehanna International Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's Recursion Pharmaceuticals position peaked at $26.3M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.